Ephenidine Stats & Data

Ephenidine is a selective NMDA receptor antagonist at the PCP site (Ki ≈ 66 nM) with modest activity at DAT/NET and sigma sites; this explains dissociation with a lightly stimulating edge in some users. Oral onset can be slow and sometimes delayed beyond 60 minutes, which increases the temptation to redose early—waiting a full 2 hours before any redose lowers the risk of overshooting. Residual stimulation, cognitive fog, and trouble sleeping can persist into the next day following strong doses; plan dosage timing accordingly (avoid late-evening starts if sleep is important). Compared with arylcyclohexylamines like ketamine, diarylethylamines have less defined data on urinary toxicity; nonetheless, users have reported bladder/urinary discomfort after heavy or frequent use—staying well-hydrated, spacing sessions widely, and stopping if urinary symptoms appear is prudent. Insufflation is frequently reported as harsh and irritating with a large chemical drip and shorter, less predictable effects; many users prefer oral or carefully prepared rectal solutions to reduce local irritation. Mixing with alcohol, GHB/GBL, or opioids markedly increases the risk of loss of consciousness, vomiting, and respiratory depression; these combinations account for many serious dissociative-related emergencies. Combining with stimulants increases heart rate and blood pressure and can precipitate anxious or manic states, particularly when sleep is missed. Dissociatives strongly impair balance and depth perception—set up a safe environment, avoid heights/water, and do not drive or cycle during or after use until fully baseline. Rapid, pronounced cross-tolerance exists across NMDA antagonists; frequent use quickly blunts effects and encourages dose escalation—spacing sessions by several weeks reduces risk. Community reagent-testing anecdotes suggest ephenidine may give an orange→brown Marquis and green Mandelin reaction; however, reagent kits cannot prove identity—use a professional drug checking service when possible.